Releases
HGEN
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Humanigen (HGEN) stock and general news. This information may help you make smarter investment decisions.
About HGEN
Humanigen, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing immuno-oncology and immunology monoclonal antibodies. The Company’s Humaneered technology platform offers a method for converting existing antibodies into engineered human antibodies designed for therapeutic use, primarily for chronic conditions. It is focused on development of lead product candidate lenzilumab, a Humaneered anti-human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody. Lenzilumab is a monoclonal antibody designed to target and neutralize human GM-CSF and prevents outcomes related to COVID-19. It is also developing lenzilumab as a treatment for autoimmune and other inflammatory conditions, including eosinophilic asthma, rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), atopic dermatitis (AD) and systemic lupus erythematosus (SLE).